Table 2.
HFD-CTR | HFD-PTC | p-value | |
---|---|---|---|
(n = 6) | (n = 6) | ||
Carbonate Substitutions (ν1CO3/ν1PO4) | 0.881 ± 0.045 | 0.932 ± 0.064 | 0.2246 |
Mineral:Matrix Ratio (ν1PO4/Amide I) | 0.971 ± 0.057 | 1.032 ± 0.152 | 0.4732 |
Mineral:Matrix Ratio (ν2PO4/Amide III) | 0.948 ± 0.105 | 0.966 ± 0.049 | 0.6796 |
Crystallinity (1/ν1PO4) | 0.095 ± 0.004 | 0.097 ± 0.006 | 0.4836 |
CML:CH2-wag (unitless) | 1.316 ± 0.227 | 1.240 ± 0.089 | 0.4113 |
PEN:CH2-wag (unitless) | 1.285 ± 0.206 | 1.309 ± 0.089 | 0.7662 |
Bound Water (I3220/I2949) | 0.390 ± 0.073 | 0.438 ± 0.161 | 0.3528 |
Data are presented as mean ± STD. CML = carboxymethyl-lysine; PEN = pentosidine; CH2 = methylene; PO4 = phosphate; CO3 = carbonate; ν1, ν2 = band mode; fAGEs = fluorescent advanced glycation end-products. Groups represent in vitro treatment with saline (HFD-CTR) or phenacyl thiazolium chloride (HFD-PTC) to femora from ten-week-old C57BL/6J male mice fed a high-fat diet (HFD) for 22 weeks, assessed by paired t-test (two tailed, α = 0.05).